Abberior installs state-of-the-art STED microscope at MBC BioLabs supporting biotech entrepreneurs

Abberior, a leading provider of cutting-edge imaging technologies, announced today that they have placed a super-resolution STED microscope at MBC BioLabs, the leading San Francisco Bay Area biotech incubator network. The installation is part of Abberior's efforts to support biotech entrepreneurs in launching and growing innovative life science companies.

Abberior installs state-of-the-art STED microscope at MBC BioLabs supporting biotech entrepreneurs
STEDYCON™ STED super-resolution fluorescence microscope. Image Credit: Abberior

The STEDYCON™ STED microscope is a super-resolution fluorescence microscope, which allows researchers to visualize biological structures and processes at the nanoscale level with high accuracy and detail. The instrument will be an essential resource for biotech entrepreneurs at MBC BioLabs, enabling them to develop new products and therapies with increased efficiency and effectiveness.

We are thrilled to bring this cutting-edge technology to MBC BioLabs and help support the next generation of biotech entrepreneurs. Our STEDYCON microscope combines cutting-edge resolution and imaging performance with ease of use, enabling researchers to make breakthrough discoveries and bring new innovations to the market."

Dr. Christian Wurm, CEO, c.

MBC BioLabs, which has locations in the heart of San Francisco’s thriving biotech community, provides a supportive and collaborative environment for biotech startups to grow and flourish. The addition of Abberior's STEDYCON is a major investment in the future of biotech innovation and will help to further position MBC BioLabs as a leading destination for life science entrepreneurs.

We are committed to providing our members with the resources and support they need to succeed, and the installation of Abberior's STED microscope is a major step forward in that effort. This tool will play a critical role in helping our startups to develop innovative products and therapies that will have a transformative impact on human health and well-being."

Dr. Doug Crawford, Founder of MBC BioLabs.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immunotherapy Advances: CAR T Cells Targeting GD2 Offer Hope for Glioma Patients